Strong Q3 Performance for SCHOTT Pharma with Sustained Growth Prospects

In the third quarter of 2026, SCHOTT Pharma reported an 8.3% revenue growth at constant currencies, driven by increased demand across its product portfolio. The nine-month revenue stood at EUR 769.8 million, a 4.4% increase from the previous year. Despite a slight drop in EBITDA margin from 28.9% to 26.7%, the company achieved a 57% revenue share in high-value solutions.

The Drug Containment Solutions segment saw revenue growth to EUR 445.4 million, while the Drug Delivery Systems segment reported a decrease to EUR 325.1 million due to reduced demand for polymer syringes for mRNA vaccines. SCHOTT Pharma focused on expanding capacities, particularly in Switzerland and Hungary, to meet the growing demand.

Outlook for 2026 remains optimistic, with expected revenue growth of 5% to 6% at constant currencies, confirmed by the company's solid financial position and ongoing investments. SCHOTT Pharma's collaboration with Nemera is aimed at enhancing patient-centric treatment models.